• where experts go to learn about FDA
  • Enforcement

    • Zarbee’s Honey-Based Cough Claims Choked by FDAJuly 8th, 2014

      By Wes Siegner – Just in time for the windup to ad campaigns for the fall/winter cold/flu season, FDA has sent Zarbee’s, Inc. a Warning Letter alerting the company that its dietary supplement products are in fact illegal drugs, some prescription drugs, given the claims that the …

    • KV Lawsuit Involving MAKENA and Compounded 17p Concludes . . . . In Sopranos StyleJuly 7th, 2014

      By Kurt R. Karst –       The years-long, knock-down, drag-out fight between the K-V Pharmaceutical Company (“KV”) – now known as Lumara Health Inc. – and FDA (and the Department of Health and Human Services) involving KV’s pre-term birth orphan drug MAKENA (hydroxyprogesterone caproate) Injection, 250 mg/mL, …

    • The Ascension of FDA’s September 19, 2011 Marketed Unapproved Drugs Compliance Policy GuideJune 2nd, 2014

      By Kurt R. Karst –       FDA’s recent announcement that the Agency seized more than $11,185,000 worth of unapproved drugs marketed by Ascend Laboratories (“Ascend”) is the latest, and most clear example yet of FDA taking action pursuant to the Agency’s September 19, 2011 Marketed Unapproved Drugs …

    • DOJ Announces Significant Policy Shift on Electronic Recordings of Statements; Will Other Agencies Follow?May 30th, 2014

      By JP Ellison & Anne K. Walsh –  On May 22, 2014, the Justice Department announced that it had made a significant policy change regarding its policy concerning whether to electronically record statements made by individuals.   A copy of the relevant DOJ memo is available here.  Beginning …

    • Race to Market: Drugs vs. Dietary Supplements; FDA Plants a LandmineMay 11th, 2014

      By Riëtte van Laack – The FDC Act, as amended by the Dietary Supplement Health and Education Act (“DSHEA”) of 1994, excludes from the definition of dietary supplement any article that is approved as a new drug and any article “authorized for investigation as a new …

    • Zogenix Sues Massachusetts Over Order Banning ZOHYDRO ER; Alleges Ban is UnconstitutionalApril 8th, 2014

      By Kurt R. Karst –     Shortly after Massachusetts Governor Deval Patrick issued a press release on March 27, 2014 announcing a Declaration of Emergency and that the Governor had directed the Massachusetts Department of Public Health (“DPH”) and its Commissioner, Cheryl Bartlett, RN, to take several actions …

    • Limitations Imposed on Use of FDA Warning LettersMarch 25th, 2014

      By Anne K. Walsh – The Supreme Court of Arkansas recently overturned (here and here) a lower court’s $1.2 billion award to the State of Arkansas, and also reversed and remanded the decision granting over $200 million in attorney’s fees and costs to the state.  Putting …

    • Court Rules that FTC’s Substantiation Requirements Are Applicable to Claims for Medical FoodsMarch 12th, 2014

      By Riëtte van Laack – Defendants Wellness Support Network, and co-owners Robert and Robyn Held, marketed two diabetes products – Diabetic Pack and Insulin Resistance – as medical foods.  In 2005 and 2006, FDA issued two Warning letters to them (here and here), claiming the products …

    • Endo Pharmaceuticals – Not Your Typical Off-Label SettlementMarch 6th, 2014

      By Anne K. Walsh – Yes, this post relates to yet another off-label settlement between a pharmaceutical company and the federal government.  But some aspects of this recent settlement, coupled with other recent cases, might indicate noteworthy trends in how these cases are being resolved.  The …

    • Every Breath You Take . . . FDA is Watching You!March 5th, 2014

      By Robert A. Dormer – Every breath you takeEvery move you makeEvery bond you breakEvery step you takeI'll be watching you Every single dayEvery word you sayEvery game you playEvery night you stayI'll be watching you Our apologies to Sting and The Police, but we were reminded of the …

    • Government Says Supreme Court Should Not Take Up False Claims Act Case Alleging Off-Label PromotionFebruary 27th, 2014

      By JP Ellison – On February 25th, the Solicitor General’s Office weighed in on whether the Supreme Court should take up a case involving False Claims Act allegations arising out of alleged off-label promotion of a drug.  The case is Nathan v. Takeda, and the United States …

    • Is the Government Entitled to Deference in FDA Criminal Cases?February 27th, 2014

      By John R. Fleder – In litigation brought by or against FDA, the agency frequently seeks to avoid a “jump-ball” by arguing that FDA’s position is entitled to deference by the court.  That argument is consistently made in civil cases and has been made in some …

    • We’ll Say It Again: Regulatory Noncompliance Does Not an FCA Case MakeFebruary 24th, 2014

      By Jennifer M. Thomas – The writers of this blog have often noted with dismay Relators’ attempts to enforce the FDCA and FDA regulations through the False Claims Act.  Here, and here, for example.  Last week, the Fourth Circuit confirmed that this is a losing strategy …

    • Speech by High-Level DOJ Official Claims Shared Interests of Prosecutors and Regulated IndustryJanuary 30th, 2014

      By JP Ellison – In a speech on January 29th at the CBI Pharmaceutical Compliance Congress that DOJ posted on its own website, U.S. Department of Justice Assistant Attorney General Stuart Delery set forth his views of the three ways that the government’s enforcement interests align with …

    • An Old Fashioned Park Criminal Prosecution With Some Twists – Part IIJanuary 30th, 2014

      By John R. Fleder – On October 2, 2013, HP&M posted the following on this blog: On September 26, 2013, the United States Attorney for the District of Colorado announced that he had filed a six count criminal Information against Eric and Ryan Jensen.  The government alleges …